Skip to content

NewAmsterdam Pharma

US · NAMS #2583 by market cap Listed 1970
18.41 -1.10 -5.64%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/11/10
  • Rating change
    A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $58
    Market Newswire · 2026/8/6
  • Company notice
    NamSys Inc: MD&A - ENGLISH
    SEDAR · 2023/3/30
  • Company notice
    NamSys Inc: MD&A - ENGLISH
    SEDAR · 2023/6/29
  • Rating change
    Citi Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/10/15
  • Company notice
    NamSys Inc: MD&A - ENGLISH
    SEDAR · 2022/9/28
  • Company notice
    NamSys Inc: MD&A - ENGLISH
    SEDAR · 2022/6/29
  • Rating change
    William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
    Market Newswire · 2026/9/18
  • BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/11/5
  • Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/11/9
  • Rating change
    Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $48
    Market Newswire · 2026/8/8
  • Cantor Fitzgerald Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $61
    Market Newswire · 2026/11/11
  • Company notice
    NamSys Inc: MD&A - ENGLISH
    SEDAR · 2023/2/25
  • Rating change
    RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $42
    Market Newswire · 2026/10/5
  • Rating change
    Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57
    Market Newswire · 2026/9/22
  • Rating change
    Wells Fargo Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/11/5
  • Rating change
    Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
    Market Newswire · 2026/9/8
  • H.C. Wainwright Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $52
    Market Newswire · 2026/11/6
  • Rating change
    RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/11/5
  • Rating change
    A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $52
    Market Newswire · 2026/8/7
  • Rating change
    RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $51
    Market Newswire · 2026/6/30
  • Rating change
    Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/5/8
  • BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/9/22
  • Rating change
    Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/8/4
  • Rating change
    Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/9/8

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

NewAmsterdam Pharma discussion 0 comments

Add a comment